Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HH2853 in relapsed/refractory peripheral T-cell lymphoma
CTR20221416Phase 2Active
- Sponsor
- Haihe
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HH2853 in peripheral T-cell lymphoma (PTCL), sponsored by Haihe. Started Aug 2022; status: active.
02
Drugs
HH2853
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on CTR20221416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221416.